Core Viewpoint - Medtronic is implementing a significant organizational adjustment in its surgical division in China to enhance efficiency and collaboration, aligning with its "One Surgical" strategy [2][10]. Group 1: Leadership Changes - The departure of Zhang Benyan, Senior Director of Medtronic China, signals a move towards streamlining management and focusing on core business units [3][6]. - Zhang Benyan has a notable background in the medical device industry, having held various key positions at Medtronic and other major companies, contributing to the development of Medtronic's surgical business in China [7]. Group 2: Organizational Adjustments - Medtronic is quickly filling leadership gaps with new appointments to ensure continuity in its surgical operations, reflecting the urgency of advancing the "One Surgical" strategy [8][9]. - Key appointments include Liu Shixiao as the Director of Downstream Market for the surgical division and Xu Simei as the National Sales Director for the anastomosis and lung health product line [11]. Group 3: Strategic Focus - The adjustments aim to break down internal barriers based on product lines, transitioning towards comprehensive clinical solutions that enhance customer engagement and operational efficiency [13]. - Medtronic's surgical business in China is a crucial growth area, with a well-established product and solution system, particularly in innovative surgical products like powered anastomosis devices [13]. Group 4: Broader Context - This organizational restructuring is part of a larger trend within Medtronic, as the company has seen multiple leadership changes globally since 2025, likely in preparation for a potential acquisition cycle in 2026 [14]. - Medtronic's financial health supports these strategic moves, with a stock price of $102.44 as of February 6, 2026, reflecting a 7.38% increase over three months, and a fiscal year 2025 revenue of $33.537 billion, up 3.7% year-over-year [14].